bluebird bio prices upsized IPO above the range at $17


Shutterstock photo

bluebird bio, a clinical-stage biotech developing gene therapies for severe genetic and orphan diseases, raised $101 million by offering 5.9 million shares at $17, above the range of $14 to $16. The company had originally planned to offer 5.0 million shares. bluebird bio will list on the NASDAQ under the symbol BLUE. bluebird bio initially filed confidentially on 3/21/2013. J.P. Morgan and BofA Merrill Lynch acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com